Emerging roles of lymphatics in inflammatory bowel disease

Annals of the New York Academy of Sciences

Volumn 1207, Issue SUPPL.1, 2010, Pages

  Steven Alexander, J ^a   Chaitanya, Ganta Vijay ^a   Grisham, M B ^a   Boktor, Moheb ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Colon; CROHN'S disease; Lymphatics; Small intestine; Ulcerative colitis

Indexed keywords

CYTOKINE; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1;

CROHN DISEASE; DENDRITIC CELL; DOWN REGULATION; ENTERITIS; FLUID BALANCE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LEUKOCYTE MIGRATION; LYMPHANGIOGENESIS; LYMPHANGITIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; ULCERATIVE COLITIS; ANIMAL; C57BL MOUSE; LYMPH VESSEL; MOUSE; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHATIC VESSELS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78049509438     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05757.x     Document Type: Review

References (76)

1. Van Kruiningen, H.J. & J.F. Colombel. 2008. The forgotten role of lymphangitis in Crohn's disease. Gut 57: 1-4.
2. Assasi, N., G. Blackhouse, F. Xie, et al. Patient outcomes after anti TNF-alpha drugs for Crohn's disease. Expert Rev. Pharmacoecon. Outcomes Res. 10: 163-175.
3. Chidlow, J.H. Jr, D. Shukla, M.B. Grisham & C.G. Kevil. 2007. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G5-G18.
4. Barrowman, J.A., P.Kwan, C.Mousseau&S.G. Turner. 1978. The effect of glucagon on intestinal lymph flow in rats. Can. J. Physiol. Pharmacol. 56: 531-532.
5. Yoffey, J.M. & F.C. Courtice. 1970. Lymphatics, Lymph and Lymphomyeloid Complex. Academic Press. New York.
6. Crohn, B.B., L. Ginzburg & G.D. Oppenheimer. 2000. Regional ileitis: a pathologic and clinical entity. 1932. Mt. Sinai J. Med. 67: 263-268.
7. Kubo, A., A. Fuchigami, A. Fujii & S. Yamada. 1970. On the treatment of the ulcerative colitis. J. Gastroenterol. 5: 257-258.
8. Heatley, R.V., P.M. Bolton, L.E. Hughes & E.W. Owen. 1980. Mesenteric lymphatic obstruction in Crohn's disease. Digestion 20: 307-313.
9. Olszewski, W.L. 1991. Lymph Stasis: Pathophysiology, Diagnosis and Treatment. CRC Press. Boca Raton, FL.
10. Oshima, T., F.S. Laroux, L.L. Coe, et al. 2001. Interferongamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc. Res. 61: 130-143.
11. Yoshida, H. & D.N. Granger. 2009. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm. Bowel Dis. 15: 1245-1255.
12. Hatoum, O.A., K.S. Spinelli, M. Bu-Hajir, et al. Mesenteric venous thrombosis in inflammatory bowel disease. J. Clin. Gastroenterol. 39: 27-31.
13. Tonelli, P. 2000. New developments in Crohn's disease: unraveling themystery of its etiopathogenesis and its reinstatement as a surgically treatable condition. Part 3: the rational principles of surgical therapy. Chir. Ital. 52: 335-342.
14. del Gaudio, A., R.B. Bragaglia, L. Boschi, et al. 1997. A new approach in themanagement of Crohn's disease: observations in 20 consecutive cases. Hepatogastroenterology 44: 1095-1103.
15. Tabibiazar, R., L. Cheung, J. Han, et al. 2006. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 3: e254.
16. Olszewski, W.L., J.Pazdur, E.Kubasiewicz, et al. 2001. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum. 44: 541-549.
17. Szczesny, G. &W.L. Olszewski. 2003. The pathomechanism of posttraumatic edema of the lower limbs: II-changes in the lymphatic system. J. Trauma 55: 350-354.
18. Cavriani, G., H.V. Domingos, R.M. Oliveira-Filho, et al. 2007. Lymphatic thoracic duct ligation modulates the serum levels of IL-1beta and IL-10 after intestinal ischemia/reperfusion in rats with the involvement of tumor necrosis factor alpha and nitric oxide. Shock 27: 209-213.
19. Olszewski, W.L., S. Jamal, B. Lukomska, et al. 1992. Immune proteins in peripheral tissue fluid-lymph in patients with filarial lymphedema of the lower limbs. Lymphology 25: 166-171.
20. Danese, S. 2008. VEGF in inflammatory bowel disease: a master regulator of mucosal immune-driven angiogenesis. Dig. Liver Dis. 40: 680-683.
21. Hatoum, O.A., J. Heidemann & D.G. Binion. 2006. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann. N.Y. Acad. Sci. 1072: 78-97.
22. Rajashekhar, G., A. Willuweit, C.E. Patterson, et al. 2006. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J. Vasc. Res. 43: 193-204.
23. Fogt, F., T.L. Pascha, P.J. Zhang, et al. 2004. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int. J. Mol. Med. 13: 211-214.
24. Kaiserling, E., S. Krober & S. Geleff. 2003. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 36: 52-61.
25. Pedica, F., C. Ligorio, P. Tonelli, et al. 2008. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 452: 57-63.
26. Geleff, S., S.F. Schoppmann & G. Oberhuber. 2003. Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. 442: 231-237.
27. Ganta, V.C., W. Cromer, G.L. Mills, et al. 2009. Angiopoietin-2 in experimental colitis. Inflamm. Bowel Dis. 16: 1029-1039.
28. Breiteneder-Geleff, S., A. Soleiman, R. Horvat, et al. 1999. [Podoplanin-a specific marker for lymphatic endothelium expressed in angiosarcoma]. Verh. Dtsch. Ges. Pathol. 83: 270-275.
29. Papa, A., F. Scaldaferri, S. Danese, et al. 2008. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig. Dis. 26: 149-155.
30. Scaldaferri, F., S. Vetrano, M. Sans, et al. 2009. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136: 585-595.
31. Baluk, P., T. Tammela, E. Ator, et al. 2005. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115: 247-257.
32. Gale, N.W., G. Thurston, S.F. Hackett, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3: 411-423.
33. Koutroubakis, I.E., C. Xidakis, K. Karmiris, et al. 2006. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur. J. Clin. Invest. 36: 127-132.
34. Dellinger, M., R. Hunter, M. Bernas, et al. 2008. Defective remodeling and maturation of the lymphatic vasculature in angiopoietin-2 deficient mice. Dev. Biol. 319: 309-320.
35. Alexander, J.S., V.C. Ganta, P.A. Jordan, M.H. Witte. 2010. Gastrointestinal lymphatics in health and disease. Pathophysiology 17: 315-335.
36. Shimoda, H., M.J. Bernas, M.H.Witte, et al. 2007. Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res. 328: 329-337.
37. Karlsen, T.V., M.J. Karkkainen, K. Alitalo & H. Wiig. 2006. Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. J. Physiol. 574: 583-596.
38. Ostanin, D.V., J. Bao, I. Koboziev, et al. 2009. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G135-G146.
39. Chaitanya, G.V., S.E. Franks, W. Cromer, et al. 2010. Inflammatory cytokines dysregulate lymphangiogenesis in vitro: implications for chronic inflammation. Lymphatic Res. Biol. (In press).
40. Ristimaki, A., K. Narko, B. Enholm, et al. 1998. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273: 8413-8418.
41. Pegu, A., S. Qin, B.A. Fallert Junecko, et al. 2008. Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol. 180: 3399-3405.
42. Ji, R.C. 2007. Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players. Curr. Med. Chem. 14: 2359-2368.
43. Nibbs, R.J., E. Kriehuber, P.D. Ponath, et al. 2001. The betachemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am. J. Pathol. 158: 867-877.
44. Groger, M., R. Loewe, W. Holnthoner, et al. 2004. IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J. Immunol. 173: 7161-7169.
45. Pullman, W.E., S. Elsbury, M. Kobayashi, et al. 1992. Enhancedmucosal cytokine production in inflammatory bowel disease. Gastroenterology 102: 529-537.
46. Jackson, D.G. 2003. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc. Med. 13: 1-7.
47. Scavelli, C., E. Weber, M. Agliano, et al. 2004. Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J. Anat. 204: 433-449.
48. Schacht, V., M.I. Ramirez, Y.K. Hong, et al. 2003. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema.EMBOJ. 22: 3546-3556.
49. Goebel, S., M. Huang, W.C. Davis, et al. 2006. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G648-G654.
50. Rafiee, P., D.J. Stein, V.M. Nelson, et al. 2010. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am. J. Physiol. Gastrointest. Liver Physiol. 298: G167-G176.
51. Tolstanova, G., T.Khomenko, X.Deng, et al. 2009. Neutralizing anti-vascular endothelial growth factor (VEGF)antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J. Pharmacol. Exp. Ther. 328: 749-757.
52. Joory, K.D., J.R. Levick, P.S. Mortimer & D.O. Bates. 2006. Vascular endothelial growth factor-C (VEGF-C) expression in normal human tissues. Lymphat. Res. Biol. 4: 73-82.
53. Van, A.G., S. Vermeire & P. Rutgeerts. 2010. The potential for disease modification in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7: 79-85.
54. Goedkoop, A.Y., M.C. Kraan, D.I. Picavet, et al. 2004. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther. 6: R326- R334.
55. Polzer, K., D.Baeten, A. Soleiman, et al. 2008. Tumournecrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints.Ann. Rheum.Dis. 67: 1610-1616.
56. Mountain, D.J., M. Singh & K. Singh. 2008. Downregulation of VEGF-D expression by interleukin-1beta in cardiac microvascular endothelial cells is mediated by MAPKs and PKCalpha/beta1. J. Cell Physiol. 215: 337-343.
57. Alitalo, K., T. Tammela & T.V. Petrova. 2005. Lymphangiogenesis in development and human disease. Nature 438: 946-953.
58. Pytowski, B., J. Goldman, K. Persaud, et al. 2005. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J. Natl. Cancer Inst. 97: 14-21.
59. Yang, H., M. Li, H. Chai, et al. 2004. Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. J. Surg. Res. 122: 249-255.
60. Benest, A.V., S.J. Harper, S.Y. Herttuala, et al. 2008. VEGFC induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc. Res. 78: 315-323.
61. Cursiefen, C., L. Chen, L.P. Borges, et al. 2004. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113: 1040-1050.
62. Fink, A.M., I. Kaltenegger, B. Schneider, et al. 2004. Serum level of VEGF-D in patients with primary lymphedema. Lymphology 37: 185-189.
63. Olinde, J., A. Tatum, S.R. Wells, et al. 2010. Gut sterilization reduces severity of inflammation, disease activity, leukocyte infiltration and angiogenesis in the mouse DSS colitismodel [abstract]. CSCR & MWAFMR.
64. Edelblum, K.L. & J.R. Turner. 2009. The tight junction in inflammatory disease: communication breakdown. Curr. Opin. Pharmacol. 9: 715-720.
65. Barreau, F., C. Madre, U. Meinzer, et al. 2010. Nod2 regulates the host response towards microflora by modulating T cell function and epithelial permeability in mouse Peyer's patches. Gut 59: 207-217.
66. Sawa, Y., T. Ueki, M.Hata, et al. 2008. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J. Histochem. Cytochem. 56: 97-109.
67. Cho, W.G., R.J. Albuquerque, M.E. Kleinman, et al. 2009. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc. Natl. Acad. Sci. USA 106: 7137-7142.
68. Vijay-kumar, M., H. Wu, J. Aitken, et al. 2007. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm. Bowel Dis. 13: 856-864.
69. Zawieja, D.C. 2009. Contractile physiology of lymphatics. Lymphat. Res. Biol. 7: 87-96.
70. Simon, M.S. & R.L. Cody. 1992. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am. J. Med. 93: 543-548.
71. Wu, T.F., W.K. Macnaughton & P.Y. von der Weid. 2005. Lymphatic vessel contractile activity and intestinal inflammation. Mem. Inst. Oswaldo Cruz 100(Suppl 1): 107-110.
72. von der Weid, P.Y. & M. Muthuchamy. 2009. Regulatory mechanisms in lymphatic vessel contraction under normal and inflammatory conditions. Pathophysiology 17: 263-276.
73. Jurisic, G., J.P. Sundberg, A. Bleich, et al. 2010. Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease. Genes Immun. 11: 219-231.
74. Van kruiningen, H.J., M. Poulin, A.E. Garmendia, et al. 2007. Search for evidence of recurring or persistent viruses in Crohn's disease. APMIS 115: 962-968.
75. Wang, H.W., M.W. Trotter, D. Lagos, et al. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36: 687-693.
76. Albuquerque, R.J., T. Hayashi, W.G. Cho, et al. 2009. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 15: 1023-1030.